The IDMC’s review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort. AMT-162 is an investigational AAVrh10-based gene therapy that ...
Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating ...
Informatica (NYSE: INFA), a leader in enterprise AI-powered cloud data management, announced that Gartner, Inc. has once again recognized the company as a Leader in the 2025 Gartner® Magic Quadrant™ ...
Clinical Trials Arena on MSN14d
Praxis Precision continues with ET trial despite likely failure warningUS-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an independent review insisted it would likely fail to meet its endpoints. An ...
14d
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Results of the Planned Interim Analysis and Update on Topline Read-out for the Essential3 Program: The Independent Data Monitoring Committee (IDMC) overseeing the interim analysis of Study 1 of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback